Secreted BMP antagonists and their role in cancer and bone metastases

Expression of BMP antagonists in cancer cells inducing osteolytic or osteoclerotic bone metastases

European Urology Supplements ◽

10.1016/s1569-9056(03)90449-0 ◽

2003 ◽

Vol 2 (6) ◽

pp. 88

Author(s):

Ruth Schwaninger ◽

Cyrill Rentsch ◽

Francisca Geissbühler ◽

Antoinette Wetterwald ◽

Irena Klima ◽

...

Keyword(s):

Bone Metastases ◽

Cancer Cells ◽

Bmp Antagonists

Download Full-text

Zoledronic acid in cancer patients with bone metastases: Results of Phase I and II trials

Seminars in Oncology ◽

10.1053/sonc.2001.24157 ◽

2001 ◽

Vol 28 (2C) ◽

pp. 25-34 ◽

Cited By ~ 1

Author(s):

James R. Berenson

Keyword(s):

Zoledronic Acid ◽

Phase I ◽

Bone Metastases ◽

Cancer Patients ◽

Phase I And Ii

Download Full-text

Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors

Seminars in Oncology ◽

10.1053/sonc.2002.37416 ◽

2002 ◽

Vol 29 (6 Suppl 21) ◽

pp. 28-32 ◽

Cited By ~ 19

Author(s):

Lee S. Rosen

Keyword(s):

Lung Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Solid Tumors ◽

Efficacy And Safety

Download Full-text

Radioiodide Treatment of Pulmonary Metastases of Differentiated Thyroid Cancer

Nuklearmedizin ◽

10.1055/s-0037-1620881 ◽

1979 ◽

Vol 18 (02) ◽

pp. 86-90 ◽

Cited By ~ 26

Author(s):

V. Zamrazil ◽

D. Pohunková ◽

S. Röhling ◽

J. Němec

Keyword(s):

Thyroid Cancer ◽

Bone Metastases ◽

Differentiated Thyroid Cancer ◽

Pulmonary Metastases ◽

Survival Rates ◽

Younger Patients ◽

131I Uptake ◽

Young Subjects ◽

Radioiodide Therapy ◽

Diagnosis Of Thyroid Cancer

Pulmonary metastases were found in 123 out of 840 patients with thyroid cancer between 1955-1977. 87 patients with pulmonary metastases of differentiated cancer were studied in detail, including an evaluation of prognostically important factors. In 66 of them, the induction of 131I uptake in metastases was attempted, in half of them successfully. Uptake was achieved more frequently in younger subjects, in papillary cancers and in patients with fine pulmonary metastases on chest films. Survival (not corrected for age) was evaluated 10 and 15 years following the diagnosis of thyroid cancer and was found to be 29,1 % and 12,2%, respectively. Significantly higher survival rates were seen in younger patients, in patients with the fine type of pulmonary metastases, in the absence of bone metastases and, particularly, in patients with induced 131I uptake in metastases. Papillary cancers were found to have higher survival rates in males and in young subjects only, in the whole group the survival rates were independent of either microscopic type or sex. It is believed that biologic behaviour of distant (pulmonary) metastases may be influenced by radioiodide therapy.

Download Full-text

131J-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem Serum-Thyreoglobulinspiegel – Ausnahme in der Tumornachsorge?

Nuklearmedizin ◽

10.1055/s-0038-1628878 ◽

1987 ◽

Vol 26 (03) ◽

pp. 139-142 ◽

Cited By ~ 4

Author(s):

G. Arning ◽

O. Schober ◽

H. Hundeshagen ◽

Ch. Ehrenheim

Keyword(s):

Serum Level ◽

Thyroid Carcinoma ◽

Bone Metastases ◽

Differentiated Thyroid Carcinoma ◽

Serum Thyroglobulin ◽

Thyroglobulin Level ◽

Low Serum

In the follow-up of differentiated thyroid carcinoma it is discussed whether the tumormarker thyroglobulin can replace the1311 scan, especially when the thyroglobulin serum level is normal. A positive1311 scan of metastases in the follow-up of patients with differentiated thyroid carcinoma combined with a low serum thyroglobulin level is extremely rare. The literature shows a frequency of about 4%. Recently we found 3 cases with a positive1311 scan demonstrating pulmonary and bone metastases whereas the serum thyroglobulin level was low.

Download Full-text